靶向肿瘤新生血管整合素αvβ3受体显像研究现状及进展

郝玉美; 贺欣; 宋娜玲; 郝玉美; 贺欣; 宋娜玲

doi:10.3760/cma.j.issn.1673-4114.2014.03.010

[1]

Liu S. Radiolabeled cyclic RGD peptides as integrin αvβ3-targeted radiotracers: maximizing binding affinity via bivalency[J]. Bioconjug Chem, 2009, 20(12): 2199-2213. doi: 10.1021/bc900167c

[2]

Herrmann K, Erkan M, Dobritz M, et al. Comparison of 3'-deoxy-3'-[¹⁸F] fluorothymidine positron emission tomography(FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours[J]. Eur J Nucl Med Mol Imaging, 2012, 39(5): 846-851. doi: 10.1007/s00259-012-2061-8

[3]

Folkman J. Tumor angiogenesis: therapeutic implications[J]. N Engl Med, 1971, 285(21): 1182-1186. doi: 10.1056/NEJM197111182852108

[4]

Hu XD, Xing LG, Yu JM. Nuclear medical molecular imaging of tumor angiogenesis: current status and future prospects[J]. Chin Med J(Engl), 2013, 126(14): 2741-2746.

[5]

刘开元, 李前伟, 刘广元.放射性标记RGD序列多肽与整合素αvβ3受体显像的研究进展[J].医学综述, 2006, 12(12): 757-759. doi: 10.3969/j.issn.1006-2084.2006.12.023

[6]

Max R, Gerritsen RR, Nooijen PT, et al. Immunohistochemical analysis of integrin αvβ3 expression on tumor-associated vessels of human carcinomas[J]. Int J Cancer, 1997, 71(3): 320-324. doi: 10.1002/(SICI)1097-0215(19970502)71:3<320::AID-IJC2>3.0.CO;2-#

[7]

王浩, 施培基, 周晓靓, 等. RGD肽及其衍生物在肿瘤显像剂治疗中的研究进展[J].国际放射医学核医学杂志, 2007, 31(5): 274-277. doi: 10.3760/cma.j.issn.1673-4114.2007.05.006

[8]

邵国强, 王自正.整合素αvβ3受体靶向肿瘤显像研究进展[J].国际放射医学核医学杂志, 2014, 38(1): 33-36.

[9]

Yu YP, Wang Q, Liu YC, et al. Molecular basis for the targeted binding of RGD-containing peptide to integrin alphaVbeta3[J]. Biomaterials, 2014, 35(5): 1667-1675. doi: 10.1016/j.biomaterials.2013.10.072

[10]

Alam IS, Witney TH, Tomasi G, et al. Radiolabeled RGD Tracer Kinetics Annotates Differential αvβ3 Integrin Expression Linked to Cell Intrinsic and Vessel Expression[J/OL]. Mol Imaging Biol, 2013[2014-03-20]. http://link.springer.com/article/10.1007%2Fs11307-013-0710-3. [published online ahead of print Dec 6, 2013].

[11]

Oxboel J, Brandt-Larsen M, Schjoeth-Eskesen C, et al. Comparison of two new angiogenesis PET tracers ⁶⁸Ga-NODAGA-E[c(RGDyK)]₂ and ⁶⁴Cu-NODAGA-E[c(RGDyK)]₂; in vivo imaging studies in human xenograft tumors[J]. Nucl Med Biol, 2014, 41(3): 259-267.

[12]

Maschauer S, Haubner R, Kuwert T, et al. ¹⁸F-Glyco-RGD Peptides for PET Imaging of Integrin Expression: Efficient Radiosynthesis by Click Chemistry and Modulation of Biodistribution by Glycosylation[J]. Mol Pharm, 2014, 11(2): 505-515. doi: 10.1021/mp4004817

[13]

Jin ZH, Furukawa T, Sogawa C, et al. PET imaging and biodistribution analysis of the effects of succinylated gelatin combined with L-lysine on renal uptake and retention of Cu-cyclam-RAFT-c(-RGDfK-)in vivo[J]. Eur J Pharm Biopharm, 2013, 86(3): 478-486.

[14]

Liu ZF, Niu G, Shi J, et al. ⁶⁸Ga-labeled cyclic RGD dimmers with Gly3 and PEG4 linkers: promising agents for tumor integrin αvβ3 PET imaging[J]. Eur J Nucl Med Mol Imaging, 2009, 36(6): 947-957. doi: 10.1007/s00259-008-1045-1

[15]

Jamous M, Haberkorn U, Mier W. Synthesis of peptide radiopharmaceuticals for the therapy and diagnosis of tumor diseases[J]. Molecules, 2013, 18(3): 3379-3409. doi: 10.3390/molecules18033379

[16]

Lewis MR, Kao JY, Anderson AL, el al. An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA[J]. Bioconjug Chem, 2001, 12(2): 320-324. doi: 10.1021/bc0000886

[17]

Zhang Y, Hong H, Engle JW, et al. Positron emission tomography imaging of CD105 expression with a ⁶⁴Cu-labeled monoclonal antibody: NOTA is superior to DOTA[J/OL]. PloS One, 2011, 6(12): e28005[2014-03-20]. http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0028005.

[18]

Yapp DT, Ferreira CL, Gill RK, et al. Imaging tumor vasculature noninvasively with positron emission tomography and RGD peptides labeled with copper 64 using the bifunctonal chelates DOTA, oxo-DO3a. and PCTA[J]. Mol Imaging, 2013, 12(4): 263-272.

[19]

王荣福, 李险峰, 王强. SPECT/CT的最新应用进展[J]. CT理论与应用研究, 2012, 21(3): 577-582.

[20]

张春丽, 杨铭, 王荣福. RGD肽与整合素αvβ3受体结合的构效关系及放射性标记配体的设计[J].肿瘤学杂志, 2009, 15(1): 76-81.

[21]

Beer A J, Lorenzen S, Metz S, et al. Comparison of integrin α_Vβ₃ expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using ¹⁸F-galacto-RGD and ¹⁸F-FDG[J]. J Nucl Med, 2008, 49(1): 22-29.

[22]

Sugiura G, Kuhn H, Sauter M, et al. Radiolabeling strategies for tumor-targeting proteinaceous drugs[J]. Molecules, 2014, 19(2): 2135-2165. doi: 10.3390/molecules19022135

[23]

Zhu Z, Yin Y, Zheng K, et al. Evaluation of synovial angiogenesis in patients with rheumatoid arthritis using ⁶⁸Ga-PRGD₂ PET/CT: a prospective proof-of-concept cohort study[J]. Ann Rheum Dis, 2014, 73(6): 1269-1272. doi: 10.1136/annrheumdis-2013-204820

[24]

Trajkovic-Arsic M, Mohajerani P, Sarantopoulos A, et al. Multimodal molecular imaging of integrin αvβ3 for in vivo detection of pancreatic cancer[J]. J Nucl Med, 2014, 55(3): 446-451.

[25]

Durkan K, Jiang Z, Rold T L, et al. A heterodimeric[RGD-Glu-[⁶⁴Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors[J]. Nucl Med Biol, 2014, 41(2): 133-139.

[26]

Shallal HM, Minn I, Banerjee SR, et al. Heterobivalent agents targeting PSMA and integrin-αvβ3[J]. Bioconjug Chem, 2014, 25(2): 393-405. doi: 10.1021/bc4005377

[27]

Rangger C, Helbok A, Sosabowski J, et al. Tumor targeting and imaging with dual-peptide conjugated multifunctional liposomal nanoparticles[J]. Int J Nanomedicine, 2013, 8: 4659-4671.

[28]

Debergh I, Van Damme N, De Naeyer D, et al. Molecular imaging of tumor-associated angiogenesis using a novel magnetic resonance imaging contrast agent targeting alphabeta integrin[J]. Ann Surg Oncol, 2013, 21(6): 2097-2104.

[29]

Ma Q, Ji B, Jia B, et al. Differential diagnosis of solitary pulmonary nodules using ^99mTc-3PI4-RGDF scintigraphy[J]. Eur J Nucl Med Mol Imaging, 2011, 38(12): 2145-2152. doi: 10.1007/s00259-011-1901-2

[30]

Zhao D, Jin X, Li F, et al. Integrin αvβ3 Imaging of Radioactive Iodine-Refractory Thyroid Cancer Using ^99mTc-3PRGD2[J]. J Nucl Med, 2012, 53(12): 1872-1877. doi: 10.2967/jnumed.112.107821

[31]

Zhu Z, Miao W, Li Q, et al. ^99mTc-3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study[J]. J Nucl Med, 2012, 53(5): 716-722. doi: 10.2967/jnumed.111.098988

[32]

Shi J, Fan D, Dong C, et al. Anti-tumor effect of integrin targeted ¹⁷⁷Lu-3PRGD2 and combined therapy with endostar[J]. Theranostics, 2014, 4(3): 256-266. doi: 10.7150/thno.7781

[33]

贺欣, 赵启仁, 宋娜玲, 等.肿瘤抑素T7肽及其衍生物T7-NGR载体构建及表达[J].生物工程, 2008, 12(3): 240-244.

[34]

郝玉美, 贺欣, 周晓靓, 等. ^99mTc标记T7肽及其在裸鼠非小细胞肺癌模型体内的生物分布研究[J].中国肺癌杂志, 2014, 17(3): 189-196.